Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial.

scientific article

Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1090679794
P356DOI10.1186/S12887-017-0923-8
P932PMC publication ID5513165
P698PubMed publication ID28709412

P50authorGiacomo CavallaroQ40566332
Luca FilippiQ55126931
Giancarlo la MarcaQ56479664
Simone DonatiQ61216937
Salvatore AversaQ82807268
P2093author name stringGianpaolo Donzelli
Eduardo Villamor
Elettra Berti
Giuseppe Buonocore
Ivan Cortinovis
Silvano Milani
Fabio Mosca
Paola Bagnoli
Gaetano Chirico
Alessandra Pugi
Giulia Forni
Chiara De Angelis
Massimo Dal Monte
Letizia Padrini
Roberta Pasqualetti
Massimo Agosti
Giulia Borsari
Barbara Tomasini
Valentina Bozzetti
Silvia Osnaghi
Paolo Tagliabue
Anna Maria Calvani
Giuseppe Nascimbeni
Angela Bossi
Pina Fortunato
Gabriella Araimo
Giulia Regiroli
Barbara Cavallotti
Maurizio Vanni
P2860cites workActivation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1Q24316075
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Q28111913
Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.Q30992212
Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trialQ31031681
Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trialQ31151291
Incidence of retinopathy of prematurity in the United States: 1997 through 2005.Q33471037
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of actionQ33574011
Current incidence of retinopathy of prematurity, 1989-1997.Q33724033
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteinsQ33775844
Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cellsQ34503191
A randomized, controlled trial of oral propranolol in infantile hemangioma.Q34668015
Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells.Q34734440
Animal models of oxygen-induced retinopathyQ35109399
Retinal neovascular markers in retinopathy of prematurity: aetiological implicationsQ35590686
Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity.Q35897076
Oral propranolol in early stages of retinopathy of prematurityQ35914596
Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9Q35942857
Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathyQ36035023
The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass IndexQ36040633
Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial).Q36249663
Changes in Course of Retinopathy of Prematurity from 1986 to 2013: Comparison of Three Studies in the United StatesQ37038705
Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for controlQ37072107
Induction of apoptosis in infantile hemangioma endothelial cells by propranololQ37207112
Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010.Q37416041
Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cellQ37452138
Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathyQ37607034
Retinopathy of prematurity and the oxygen conundrum: lessons learned from recent randomized trialsQ38110392
Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent mannerQ38887434
Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathwayQ38904889
Regulation of glucose transporter protein-1 and vascular endothelial growth factor by hypoxia inducible factor 1α under hypoxic conditions in Hep-2 human cellsQ39280277
Beta-adrenergic receptor regulation of pigment epithelial-derived factor expression in rat retinaQ40413462
Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progressionQ42434242
Oxygen-induced retinopathy: a model for vascular pathology in the retina.Q43221726
Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapyQ43449364
A rapid liquid chromatography tandem mass spectrometry-based method for measuring propranolol on dried blood spotsQ43486702
A randomized controlled trial of propranolol for infantile hemangiomasQ44267196
Beta-adrenergic receptor regulation of growth factor protein levels in human choroidal endothelial cellsQ44635814
Propranolol concentrations after oral administration in term and preterm neonates.Q44663019
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cellsQ44733494
Risk factors of retinopathy of prematurity in premature infants weighing less than 1600 g.Q45283096
Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants.Q45418272
Stabilization of the retinal vascular network by reciprocal feedback between blood vessels and astrocytes.Q46404558
Optimal two-stage designs for phase II clinical trialsQ46412217
Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lectureQ46425533
Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularizationQ46459264
Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic systemQ46766115
Role of beta-adrenergic receptors in inflammatory marker expression in Müller cellsQ46930340
Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurityQ47629197
Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization.Q47880195
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectivesQ47968906
Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.Q50442563
Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial.Q51425178
Infantile hemangiomas and retinopathy of prematurity: possible association.Q51818134
Antiangiogenic effects of β2 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy.Q51851194
Role of host β1- and β2-adrenergic receptors in a murine model of B16 melanoma: functional involvement of β3-adrenergic receptors.Q53574698
Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity.Q54524067
Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective studyQ56989404
Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of ageQ56996636
Prenatal Risk Factors for Severe Retinopathy of Prematurity Among Very Preterm Infants of the Australian and New Zealand Neonatal NetworkQ57391156
Impact of Placental Restriction on the Development of the Sympathoadrenal SystemQ59709862
Pharmacokinetics and local safety profile of propranolol eye drops in rabbitsQ61700384
Oxygen-induced retinopathy in the mouseQ71608431
Causes of blindness and severe visual impairment in children in ChileQ72361775
Age-related changes in sympathetic neurotransmission in rat retina and choroidQ79316686
Retinopathy of prematurityQ79858093
The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity studyQ81920787
Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains?Q85318492
Screening examination of premature infants for retinopathy of prematurityQ85818525
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in miceQ86489017
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectretinopathy of prematurityQ1423087
multicenter clinical trialQ6934595
phase II clinical trialQ42824440
study protocolQ111908491
P304page(s)165
P577publication date2017-07-14
P1433published inBMC PediatricsQ15750892
P1476titleStudy protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial
P478volume17

Reverse relations

cites work (P2860)
Q56527442Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial
Q64249029Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study
Q47708800The Beta Adrenergic Receptor Blocker Propranolol Counteracts Retinal Dysfunction in a Mouse Model of Oxygen Induced Retinopathy: Restoring the Balance between Apoptosis and Autophagy.

Search more.